RxSight, Inc. (RXST) News
Track canonical SquawkNews coverage tagged to RXST, RxSight, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 12 indexed stories across 5 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
RXST GKOS SGHT BLCO COO STAA Medical Supplies and Devices initiation - resuming coverage across the Vision sector (Neutral rated GKOS, Neutr
RXST GKOS SGHT BLCO COO STAA Medical Supplies and Devices initiation - resuming coverage across the Vision sector (Neutral rated GKOS, Neutral rated RXST, Buy rated SGHT) and initiating coverage of Buy rated BLCO, Neutra
EQUITY | Jul 28, 2026, 11:52 AM UTC
L
BAX DXCM ENOV HSIC NUE OVV OZK TFII ABT AMZN ATRC BBNX BKR BSX CEG MCB NRG RXST SGHT TNDM VST PT changes @ UBS
BAX DXCM ENOV HSIC NUE OVV OZK TFII ABT AMZN ATRC BBNX BKR BSX CEG MCB NRG RXST SGHT TNDM VST PT changes @ UBS
EQUITY | Jul 28, 2026, 11:47 AM UTC
L
Top Initiations: ATEC BDX BLCO EW SGHT SIBN STE ZBH: BUY @ UBS COO GKOS GMED IART RXST TFX TMDX: NEUTRAL @ UBS INSP STAA: SELL @ UBS BNTC: O
Top Initiations: ATEC BDX BLCO EW SGHT SIBN STE ZBH: BUY @ UBS COO GKOS GMED IART RXST TFX TMDX: NEUTRAL @ UBS INSP STAA: SELL @ UBS BNTC: OUTPERFORM @ Wedbush CRWD: BUY @ Loop FTH: OUTPERFORM @ Opp HRB: EQUAL WEIGHT @ S
EQUITY | Jul 28, 2026, 11:11 AM UTC
L
RXST - RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
RXST - RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
EQUITY | Jul 26, 2026, 08:00 PM UTC
H
RxSight Names Aziz Mottiwala as CEO
() -- RxSight (RXST) said late Wednesday its board has appointed Aziz Mottiwala as president and chief executive officer, starting July 20. Mottiwala succeeds Ron Kurtz, who will continue to serve as chief medical office
EARNINGS | Jul 15, 2026, 08:43 PM UTC
H
RXST Rxsight announces appointments of aziz mottiwala as Chief Executive Officer and Ron kurtz, M.D. as chief Medical officer Rxsight Inc: n
RXST Rxsight announces appointments of aziz mottiwala as Chief Executive Officer and Ron kurtz, M.D. as chief Medical officer Rxsight Inc: not updating previously communicated financial guidance in Connection with this a
EARNINGS | Jul 15, 2026, 08:16 PM UTC
H
RxSight raises FY26 revenue view to $140M-$160M from $120M-$135M
Consensus $129.24M. The company said that the FY26 revenue view is inclusive of RxSight sales and revenue recognized from the RxSight Alcon Strategic Collaboration, comprised of: Sales of $110M-$120M, below previous guid
EARNINGS | Jul 07, 2026, 07:49 PM UTC
L
RxSight reports preliminary Q2 revenue $32M-$34M, consensus $32.07M
Yesterday, the company said that the preliminary revenue view includes $5M-$7M in revenue recognized from the RxSight Alcon Strategic Collaboration, with the specific amount expected to be reported with the company's fin
EARNINGS | Jul 07, 2026, 07:47 PM UTC
H
RxSight price target lowered to $6.50 from $7.50 at Jefferies
Jefferies lowered the firm's price target on RxSight to $6.50 from $7.50 and keeps a Hold rating on the shares. Q2 preliminary results missed due to competitive trialing and macro pressures, as the company expects the tr
EARNINGS | Jul 07, 2026, 07:37 PM UTC
H
RxSight price target lowered to $6.50 from $8 at BofA
BofA lowered the firm's price target on RxSight to $6.50 from $8 and keeps an Underperform rating on the shares. The firm notes the company pre-announced preliminary Q2 sales of $27M vs Street of $32M and lowered 2026 gu
EQUITY | Jul 07, 2026, 04:50 PM UTC
H
RxSight Raises FY2026 Sales Guidance from $120.000M-$135.000M to $140.000M-$160.000M vs $129.250M Est
RxSight (NASDAQ: RXST ) raises FY2026 sales outlook from $120.000 million-$135.000 million to $140.000 million-$160.000 million vs $129.250 million estimate.
EARNINGS | Jul 06, 2026, 08:50 PM UTC
H
RxSight Sees Q2 Revenue Of $32M-$34M; Sees FY2026 Revenue Of $140M-$160M
RxSight, Inc. (NASDAQ: RXST ) today announced select preliminary financial results for the second quarter of 2026 and updates to its standalone product pipeline, following the announcement of the company’s strategic coll
EARNINGS | Jul 06, 2026, 08:18 PM UTC